Abstract Library

#4643 Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,

#4571 Characterisation and prognostic impact of carcinoid syndrome in bronchial neuroendocrine tumours

Introduction: Metastatic bronchial neuroendocrine tumours (MBNET) are associated with carcinoid syndrome in 10 to 40% of cases. Characteristics of carcinoid heart disease (CHD) are poorly described.

Conference:

Presenting Author: Baudin E

Authors: Hescot S, Marret G, Hadoux J, Laboureau S, Haissaguerre M,

Keywords: bronchial NET, carcinoid syndrome, 5HIAA, carcinoid heart disease,

#4360 Real-world practice patterns of 177Lu-DOTATATE in neuroendocrine tumours: A GTE national survey

Introduction: 177Lu-DOTATATE is a standard treatment for neuroendocrine tumours. Grade 3/4 hematologic toxicity affects about 5-10% of patients, with a 2-4% risk of secondary malignant hematologic disorders.

Conference:

Presenting Author:

Authors: Oziel-Taieb S, Ansquer C, Deshayes E, Haissaguerre M,

Keywords: 177Lu-DOTATATE, haematological toxicity, thrombocytopenia, neuroendocrine tumour, toxicity management,

#3710 Morphological response on mesenteric mass of small intestinal neuroendocrine tumors treated by 177Lu-DOTATATE: MESENLUTH – A GTE-ENDOCAN study

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) often metastasize, especially to mesenteric lymph nodes, which are frequently affected by fibrosis reactions due to local serotonin secretion. Peptide receptor radionuclide therapy (PRRT) with177Lu-Dotatate has shown its efficacy in the treatment of progressive SI-NETs.

Conference:

Presenting Author: Walter T

Authors: Al Mansour L, de Mestier L, Haissaguerre M, Afchain P, Hadoux J,

Keywords: neuroendocrine tumor, mesenteric mass, objective response, 177Lu-DOTATATE,

#3377 Antisecretory effect of oral targeted therapies in advanced functioning neuroendocrine tumors (the ASSET-NET study)

Introduction: Oral targeted therapies (TTs),everolimus and sunitinib,have demonstrated antitumor activity in patients with advanced progressive neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: Perrier M, Walter T, Do Cao C, Coriat R, Haissaguerre M,

Keywords: functional syndrome, targeted therapy, neuroendocrine tumor, antisecretory effect,